Firth Joseph, Teasdale Scott B, Allott Kelly, Siskind Dan, Marx Wolfgang, Cotter Jack, Veronese Nicola, Schuch Felipe, Smith Lee, Solmi Marco, Carvalho André F, Vancampfort Davy, Berk Michael, Stubbs Brendon, Sarris Jerome
NICM Health Research Institute, Western Sydney University, Westmead, Australia.
Division of Psychology and Mental Health, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
World Psychiatry. 2019 Oct;18(3):308-324. doi: 10.1002/wps.20672.
The role of nutrition in mental health is becoming increasingly acknowledged. Along with dietary intake, nutrition can also be obtained from "nutrient supplements", such as polyunsaturated fatty acids (PUFAs), vitamins, minerals, antioxidants, amino acids and pre/probiotic supplements. Recently, a large number of meta-analyses have emerged examining nutrient supplements in the treatment of mental disorders. To produce a meta-review of this top-tier evidence, we identified, synthesized and appraised all meta-analyses of randomized controlled trials (RCTs) reporting on the efficacy and safety of nutrient supplements in common and severe mental disorders. Our systematic search identified 33 meta-analyses of placebo-controlled RCTs, with primary analyses including outcome data from 10,951 individuals. The strongest evidence was found for PUFAs (particularly as eicosapentaenoic acid) as an adjunctive treatment for depression. More nascent evidence suggested that PUFAs may also be beneficial for attention-deficit/hyperactivity disorder, whereas there was no evidence for schizophrenia. Folate-based supplements were widely researched as adjunctive treatments for depression and schizophrenia, with positive effects from RCTs of high-dose methylfolate in major depressive disorder. There was emergent evidence for N-acetylcysteine as a useful adjunctive treatment in mood disorders and schizophrenia. All nutrient supplements had good safety profiles, with no evidence of serious adverse effects or contraindications with psychiatric medications. In conclusion, clinicians should be informed of the nutrient supplements with established efficacy for certain conditions (such as eicosapentaenoic acid in depression), but also made aware of those currently lacking evidentiary support. Future research should aim to determine which individuals may benefit most from evidence-based supplements, to further elucidate the underlying mechanisms.
营养在心理健康中的作用日益得到认可。除了饮食摄入外,营养还可以从“营养补充剂”中获取,如多不饱和脂肪酸(PUFAs)、维生素、矿物质、抗氧化剂、氨基酸以及益生元/益生菌补充剂。最近,出现了大量的荟萃分析,研究营养补充剂在治疗精神障碍方面的作用。为了对这一顶级证据进行荟萃综述,我们识别、综合并评估了所有关于营养补充剂在常见和严重精神障碍中的疗效和安全性的随机对照试验(RCT)的荟萃分析。我们的系统检索确定了33项安慰剂对照RCT的荟萃分析,主要分析包括来自10951名个体的结果数据。发现PUFAs(特别是二十碳五烯酸)作为抑郁症辅助治疗的证据最为充分。更多新出现的证据表明,PUFAs可能对注意力缺陷多动障碍也有益,而对精神分裂症则没有证据支持。基于叶酸的补充剂作为抑郁症和精神分裂症的辅助治疗进行了广泛研究,高剂量甲基叶酸在重度抑郁症的RCT中有积极效果。有新出现的证据表明N-乙酰半胱氨酸作为情绪障碍和精神分裂症的有效辅助治疗。所有营养补充剂都有良好的安全性,没有证据表明有严重不良反应或与精神科药物有禁忌。总之,临床医生应了解对某些病症有既定疗效的营养补充剂(如抑郁症中的二十碳五烯酸),但也要意识到那些目前缺乏证据支持的补充剂。未来的研究应旨在确定哪些个体可能从循证补充剂中获益最大,以进一步阐明潜在机制。